Objectives: Among the challenges in conducting clinical trials in large-vessel vasculitis (LVV), including both giant cell arteritis (GCA) and Takayasu's arteritis (TAK) is the lack of standardized and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT)
Introduction:
Several vasculitides fall under the definition of large-vessel vasculitis (LVV), including giant cell arteritis (GCA) and Takayasu's arteritis (TAK) (1). Clinical research in LVV has been hindered by the lack of standardized outcome measures (2) . The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group leads efforts to develop and advance development outcome measures in vasculitis, including LVV. Leading up to and during the 2016 OMERACT meeting, a "virtual Special Interest Group" was conducted to discuss the current research findings and propose a preliminary core set of domains. The main discussion points were: a) results of the international LVV Delphi (manuscript submitted); b) findings of the qualitative studies in TAK (manuscript in preparation); and c) current work on LVV disease activity and damage measures (Abstracts at OMERACT). Following the discussion, a preliminary core set of domains common to LVV with disease-specific elements was proposed.
Methods/Results:

Delphi exercise:
Given the lack of international consensus on outcome measures to assess LVV, the LVV Task Force conducted an international Delphi exercise to obtain experts' opinions regarding important disease domains for the assessment of disease outcomes in LVV (manuscript submitted for publication). Key findings emerging from this exercise include: i) many domains were common to TAK and GCA but some were distinctly identified with one or the other disease; ii) patient global assessment (PtGA) was accepted as a tool to assess patient-reported outcomes (PRO) in LVV; iii) the majority of experts agreed to have a common outcome measure tool for both GCA and TAK but that such a measure also be supplemented by disease-specific items for trials of GCA and TAK.
Patient interviews/qualitative research:
Generic PRO instruments such as the 36-item short form health survey (SF-36) and PtGA have been previously examined in patients with LVV (3) (4) (5) (6) . However, these instruments often lack the granularity and ability to capture essential disease-specific domains that are of high importance to patients with LVV. The LVV Task Force has completed individual interviews and focus groups with patients in the United States and Turkey to identify key health-related domains that patients consider important in TAK. Thirty-one patients participated. The most common themes and domains that emerged were pain and discomfort, fatigue and low energy levels, and emotional impact; a manuscript detailing this work has been prepared. Similar qualitative research is now being planned for patients with GCA to identify similarities and differences between the two diseases.
The OMERACT SIG group felt the results of these data about patient preferences should be combined with the results of the Delphi about physician opinions to form the basis of the draft core set of domains.
Assessment of disease activity:
There currently exists no clear definition of disease activity in LVV. Several disease activity assessment tools have been used in clinical trials of LVV. These tools often use a combination of clinical symptoms, cumulative glucocorticoid dose/duration and acute phase reactants. In terms of a single tool, The NIH criteria for active disease (7), the Birmingham Vasculitis Activity Score (BVAS)(8), the Disease Extent Index for Takayasu's arteritis (DEI.Tak) (9) , and the Indian Takayasu's Arteritis Score 2010 (ITAS2010) (10, 11) have all been used in clinical research for TAK (12) (13) (14) . A similar disease-specific tool does not exist for GCA and a recent study lead by investigators within the OMERACT Vasculitis Working Group found BVAS to have limited utility in GCA (19) . A combination of clinical symptoms, glucocorticoids dose or duration, and/or BVAS has been used in clinical trials of GCA (13, (15) (16) (17) (18) .
Imaging has emerged as a promising diagnostic and critical tool to follow the disease course of patients with LVV. Imaging modalities for LVV include color duplex ultrasonography (20) (21) (22) , computed tomography angiography (23, 24) , magnetic resonance angiography (25) (26) (27) (28) , and 18F fluorodeoxyglucose positron emission tomography either alone or with computed tomography (29) (30) (31) (32) . These modalities differ in terms of test characteristics, cost, exposure to radiation, and availability. While there have been tremendous advances in imaging technologies in recent years, there is a need for formal validation of imaging modalities for correlation with activity, damage, and outcome in LVV. There remain major uncertainties about the meaning of radiographic changes in arterial walls (thickening, enhancement, high signal) regarding disease activity and prognosis.
Assessment of disease damage:
Besides the Takayasu's Arteritis Damage Score, there have been no other disease-specific damage indices validated for LVV (33) . While the Vasculitis Damage Index (VDI) has been used to assess damage in LVV (34, 35) (7) and the lack of appropriate specificity and sensitivity of acute phase reactants (37, 38) . Additionally, using a dichotomous outcome measure such as active disease versus remission may miss a scale of response that is not necessarily captured in relapse-free survival assessment. Finally, if the recently-studied biologic therapies prove to be highly effective as glucocorticoid-sparing agents in LVV, they may alter the need or approach to measure cumulative glucocorticoid dose/duration variable as an outcome measure.
The OMERACT SIG group recognizes that new measures of disease activity in LVV need to be developed that incorporate several approaches, including PROs and imaging. It is anticipated that analysis of data from recently-completed and ongoing clinical trials in GCA and TAK will help advance disease assessment in LVV.
Proposal of a preliminary core set of domains in LVV:
As previously mentioned, the majority of experts in LVV voted through the Delphi exercise to have common outcome domains and measures for GCA and TAK supplemented with disease- 2-Initiate qualitative interviews with patients with GCA to identify key themes and domains of high importance to patients with GCA.
3-Determine the differences and commonalities between GCA and TAK regarding disease experience that can assist in identifying disease-specific domains of interest. 4-Consider whether there is a strong need to develop a disease-specific PRO for GCA and/or TAK.
5-Incorporate data on the utility of imaging modalities in GCA and TAK into the outcome development program for LVV.
6-Finalize a draft core set of domains and identify the best candidate tools to measure these domains. The suggested core domains fall under the mandatory core areas of OMERACT filter 2.0: *Death, ‡life impact, and †pathophysiologic manifestations.
